Document is current

Article History

Accepted: 22 November 2021

First Online: 21 December 2021

Declarations

:

: The authors are supported in part by National Institutes of Health/National Cancer Institute Cancer Center Support Grant P30 CA008748.

: LER has served as a consultant for AbbVie, AstraZeneca, Beigene, Jansen, LOXO Oncology, Pharmacyclics, Pfizer, TG Therapeutics, Vaniam group, and Verastem; holds minority ownership interest in Abbott Laboratories; and has received research funding (paid to the institution) from Pfizer and Aptose Biosciences outside of the submitted work. MT has received honoraria from MJH Life Sciences, VJ Heme Onc, and Curio Science. ARM has received grants and personal fees from, and been a data safety monitoring board member for, TG Therapeutics; has received grants and personal fees from Loxo Oncology (a wholly owned subsidiary of Eli Lilly), Genentech, AbbVie, AstraZeneca, Adaptive, Pharmacyclics, Genentech, Pharmacyclics, Janssen, Pfizer, Nurix, Genmab, and Curio Sciences; has received grants from Sunesis, Regeneron, Aprea, Aptose, and DTRM; and has received nonfinancial support from NCCN, the CLL Society, the Leukemia and Lymphoma Society, and the Lymphoma Research Foundation.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: All authors wrote and edited this manuscript.